NASDAQ: LFCR
Lifecore Biomedical Inc Stock

$4.54+0.00 (+0%)
Updated Aug 28, 2026
LFCR Price
$4.54
Fair Value Price
N/A
Market Cap
$171.85M
52 Week Low
$3.63
52 Week High
$8.98
P/E
-3.91x
P/B
-5.04x
P/S
1.49x
PEG
N/A
Dividend Yield
N/A
Revenue
$132.88M
Earnings
-$39.10M
Gross Margin
30.3%
Operating Margin
-5.83%
Profit Margin
-32.5%
Debt to Equity
-6.26
Operating Cash Flow
$10M
Beta
1.12
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

LFCR Overview

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine LFCR's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More

Zen Rating Component Grades

C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Pharmaceutical

Industry Rating
B
LFCR
Ranked
#43 of 58

Top Ranked Stocks in Industry

View Top Pharmaceutical Stocks

Be the first to know about important LFCR news, forecast changes, insider trades & much more!

LFCR News

Overview

Due Diligence Score

Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LFCR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

LFCR is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
LFCR is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
LFCR's Earnings (EBIT) of -$7.75M... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more LFCR due diligence checks available for Premium users.

Valuation

LFCR fair value

Fair Value of LFCR stock based on Discounted Cash Flow (DCF)

Price
$4.54
Fair Value
-$4.74
Undervalued by
195.75%
LFCR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

LFCR price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-3.91x
Industry
2.6x
Market
40.56x

LFCR price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
-5.04x
Industry
1.65x

LFCR's financial health

Profit margin

Revenue
$34.2M
Net Income
-$6.2M
Profit Margin
-20.9%
LFCR's Earnings (EBIT) of -$7.75M... subscribe to Premium to read more.
Interest Coverage Financials
LFCR's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$229.5M
Liabilities
$213.4M
Debt to equity
-6.26
LFCR's short-term assets ($83.69M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LFCR's long-term liabilities ($191.77M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LFCR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
LFCR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$2.2M
Investing
-$513.0k
Financing
-$852.0k
LFCR's operating cash flow ($9.84M)... subscribe to Premium to read more.
Debt Coverage Financials

LFCR vs Pharmaceutical Stocks

TickerZen RatingMarket Cap1d %P/EP/B
LFCRC$171.85M0.00%-3.91x-5.04x
OGIC$171.29M-1.22%2.71x0.49x
DERMB$210.84M-0.80%-33.95x6.57x
CPIXC$126.76M-2.20%-11.59x7.27x
SIGAC$219.86M0.00%-76.50x1.33x

Lifecore Biomedical Stock FAQ

What is Lifecore Biomedical's quote symbol?

(NASDAQ: LFCR) Lifecore Biomedical trades on the NASDAQ under the ticker symbol LFCR. Lifecore Biomedical stock quotes can also be displayed as NASDAQ: LFCR.

If you're new to stock investing, here's how to buy Lifecore Biomedical stock.

What is the 52 week high and low for Lifecore Biomedical (NASDAQ: LFCR)?

(NASDAQ: LFCR) Lifecore Biomedical's 52-week high was $8.98, and its 52-week low was $3.63. It is currently -49.44% from its 52-week high and 25.24% from its 52-week low.

How much is Lifecore Biomedical stock worth today?

(NASDAQ: LFCR) Lifecore Biomedical currently has 37,853,060 outstanding shares. With Lifecore Biomedical stock trading at $4.54 per share, the total value of Lifecore Biomedical stock (market capitalization) is $171.85M.

Lifecore Biomedical stock was originally listed at a price of $3.50 in Dec 31, 1997. If you had invested in Lifecore Biomedical stock at $3.50, your return over the last 28 years would have been 29.71%, for an annualized return of 0.93% (not including any dividends or dividend reinvestments).

How much is Lifecore Biomedical's stock price per share?

(NASDAQ: LFCR) Lifecore Biomedical stock price per share is $4.54 today (as of Aug 28, 2026).

What is Lifecore Biomedical's Market Cap?

(NASDAQ: LFCR) Lifecore Biomedical's market cap is $171.85M, as of Aug 30, 2026.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Lifecore Biomedical's market cap is calculated by multiplying LFCR's current stock price of $4.54 by LFCR's total outstanding shares of 37,853,060.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.